Skip to content
BY-NC-ND 3.0 license Open Access Published by De Gruyter April 24, 2015

Corticosteroids in oncology: An overview

  • Moretti Luigi EMAIL logo

Abstract

Corticosteroids play an important role in clinical oncology, and they may be used alone or in combination with other treatments in the therapy of cancer patients. Commonly they may be used to decrease inflammations. In this overview, by discussions on the applications of corticosteroids that are mainly used in oncology, we suggest that careful use of Corticosteroids is required and the balance between risks and benefits should always be considered in clinical oncology.

References

1. Eichenauer DA, Engert A, Dreyling M, ESMO Guidelines Working Group. Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22 Suppl 6:vi55-8.10.1093/annonc/mdr378Search in Google Scholar

2. Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: Diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol 2013;24:561-76.Search in Google Scholar

3. Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O, et al. ESMO Consensus conferences: Guidelines on malignant lymphoma. part 2: Marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 2013;24:857-77.10.1093/annonc/mds643Search in Google Scholar

4. Moreau P, San Miguel J, Ludwig H, Schouten H, Mohty M, Dimopoulos M, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24 Suppl 6:vi133-7.10.1093/annonc/mdt297Search in Google Scholar

5. Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksaç M, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: Meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 2011;118:1239-47.10.1182/blood-2011-03-341669Search in Google Scholar

6. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-17.10.1056/NEJMoa0801479Search in Google Scholar

7. Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 2004;64:1757-64.10.1158/0008-5472.CAN-03-2546Search in Google Scholar

8. Huang Y, Johnson KR, Norris JS, Fan W. Nuclear factor-kappaB/ IkappaB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res 2000;60:4426-32.Search in Google Scholar

9. Herr I, Pfitzenmaier J. Glucocorticoid use in prostate cancer and other solid tumours: Implications for effectiveness of cytotoxic treatment and metastases. Lancet Oncol 2006;7:425-30.10.1016/S1470-2045(06)70694-5Search in Google Scholar

10. Millar BM, Bezjak A, Tsao M, Sturdza A, Laperriere N. Defining the impact and contribution of steroids in patients receiving whole-brain irradiation for cerebral metastases. Clin Oncol (R Coll Radiol) 2004;16:339-44.10.1016/j.clon.2004.03.015Search in Google Scholar PubMed

11. Edwards MS, Prados M. Current management of brain stem gliomas. Pediatr Neurosci 1987;13:309-15.10.1159/000120349Search in Google Scholar PubMed

12. Hempen C, Weiss E, Hess CF. Dexamethasone treatment in patients with brain metastases and primary brain tumors: Do the benefits outweigh the side-effects? Support Care Cancer 2002;10:322-8.Search in Google Scholar

13. Weissman DE. Glucocorticoid treatment for brain metastases and epidural spinal cord compression: A review. J Clin Oncol 1988;6:543-51.10.1200/JCO.1988.6.3.543Search in Google Scholar PubMed

14. Sørensen S, Helweg-Larsen S, Mouridsen H, Hansen HH. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: A randomised trial. Eur J Cancer 1994;30A:22-7.10.1016/S0959-8049(05)80011-5Search in Google Scholar

15. Vecht CJ, Hovestadt A, Verbiest HB, van Vliet JJ, van Putten WL. Doseeffect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: A randomized study of doses of 4, 8, and 16 mg per day. Neurology 1994;44:675-80.10.1212/WNL.44.4.675Search in Google Scholar

16. Spain RC. The case for mitomycin in non-small cell lung cancer. Oncology 1993;50 Suppl 1:35-50.10.1159/000227246Search in Google Scholar

17. Kemp C. Metastatic spread and common symptoms. Part One: Introduction, bladder cancer, and brain cancer. Am J Hosp Palliat Care 1998;15:355-60.10.1177/104990919801500609Search in Google Scholar

18. Kemp C. Breast cancer, colorectal cancer, and esophageal cancer. Am J Hosp Palliat Care 1999;16:403-11.10.1177/104990919901600111Search in Google Scholar

19. Kemp C. Kidney cancer, leukemia, and liver cancer. Part 3. Am J Hosp Palliat Care 1999;16:479-86.Search in Google Scholar

20. Walsh TD, West TS. Controlling symptoms in advanced cancer. Br Med J (Clin Res Ed). 1988 13;296:477-81.10.1136/bmj.296.6620.477Search in Google Scholar

21. Aapro MS. Corticosteroids as antiemetics. Recent Results Cancer Res 1988;108:102-11.10.1007/978-3-642-82932-1_13Search in Google Scholar

22. Sorbe B, Högberg T, Himmelmann A, Schmidt M, Räisänen I, Stockmeyer M, et al. Efficacy and tolerability of tropisetron in comparison with a combination of tropisetron and dexamethasone in the control of nausea and vomiting induced by cisplatin-containing chemotherapy. Eur J Cancer 1994;30A:629-34.10.1016/0959-8049(94)90534-7Search in Google Scholar

23. Lai YL, Fang FM, Yeh CY. Management of anorexic patients in radiotherapy: A prospective randomized comparison of megestrol and prednisolone. J Pain Symptom Manage 1994;9:265-8.10.1016/0885-3924(94)90104-XSearch in Google Scholar

24. Attie MF. Treatment of hypercalcemia. Endocrinol Metab Clin North Am 1989;18:807-28.10.1016/S0889-8529(18)30368-2Search in Google Scholar

25. Truhan AP, Ahmed AR. Corticosteroids: A review with emphasis on complications of prolonged systemic therapy. Ann Allergy 1989;62:375-91.Search in Google Scholar

26. Mandel S. Steroid myopathy. Insidious cause of muscle weakness. Postgrad Med 1982;72:207-10, 213.10.1080/00325481.1982.11716260Search in Google Scholar

27. Patschan D, Loddenkemper K, Buttgereit F. Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone 2001;29:498-505.10.1016/S8756-3282(01)00610-XSearch in Google Scholar

28. Parrillo JE, Fauci AS. Mechanisms of glucocorticoid action on immune processes. Annu Rev Pharmacol Toxicol 1979;19:179-201.10.1146/annurev.pa.19.040179.001143Search in Google Scholar PubMed

29. Lupien SJ, Nair NP, Brière S, Maheu F, Tu MT, Lemay M, et al. Increased cortisol levels and impaired cognition in human aging: Implication for depression and dementia in later life. Rev Neurosci 1999;10:117-39.10.1515/REVNEURO.1999.10.2.117Search in Google Scholar PubMed

Published Online: 2015-4-24
Published in Print: 2014-6-1

© 2015

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Downloaded on 19.3.2024 from https://www.degruyter.com/document/doi/10.4103/2224-4018.135608/html
Scroll to top button